B
Biond Biologics
Innovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients
About Biond Biologics
Biond Biologics is a biotechnology company focused on developing innovative therapies for novel oncology targets. The company operates in the biopharmaceutical market, aiming to uncover immunoregulatory pathways and enable the intracellular delivery of biologics. Biond Biologics serves clients in the pharmaceutical and healthcare sectors, including global pharma companies through collaborations and partnerships. The business model revolves around research and development (R&D) of proprietary technology platforms and novel therapeutic agents, such as BND-22, a macrophage activator currently in IND-enabling studies. The company generates revenue through strategic partnerships, licensing agreements, and financing rounds, including a completed Series B financing with participation from global biopharma companies. Biond Biologics has established a sustainable R&D hub in the Galilee, Israel, and continues to advance its pipeline of oncology therapies through rigorous proof-of-concept studies and clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 30.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Developer Tools, Biotechnology, Oncology, Autoimmune, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2026 | $8M | $85M | Guangzhou Industrial Investment Fund | ↗ |
| SERIES C✓Equity / VC | Nov 2021 | $15M | $85M | Heritage Group · Deep Insight · Harel Group | — |
Growth signals
Latest recorded traffic for Biond Biologics is 320 monthly website visits, up 255.6% over the last three months. Biond Biologics's team declined 2.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Biond Biologics in the Misgav Am ecosystem
The Biond Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Israel Biotech Fund
Harel Group- SFSBI JI Innovation Fund
Celgene
Series B and later3 investors entered at this stage
Deep Insight
Heritage Group
Guangzhou Industrial Investment Fund
Other known investors1 additional known investor
GUTS Innovation
Source: Dealroom Talent Intelligence.
See Biond Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









